Related scientific articles (all)

A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.

Authors : Schöffski P, Aftimos P, Dumez H, Deleporte A, De Block K, Costermans J, Billiet M, Meeus MA, Lee C, Schnell D, Goeldner RG, Awada A
Year : 2016
Journal : Cancer Chemother Pharmacol
Volume : 77(1)
Pages : 99-108

The immunomodulatory properties of human bone marrow-derived mesenchymal stromal cells are defined according to multiple immunobiological criteria.

Authors : Fayyad-Kazan H, Faour WH, Badran B, Lagneaux L, Najar M
Year : 2016
Journal : Inflamm Res
Volume : 65(6)
Pages : 501-10

Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians.

Authors : van Cutsem E, Verheul HM, Flamen P, Rougier P, Beets-Tan R, Glynne-Jones R, Seufferlein T
Year : 2016
Journal : Cancers (Basel)
Volume : 8

Checkpoint inhibitors: outstanding efficacy but at what cost?

Authors : Klastersky J
Year : 2016
Journal : Curr Opin Oncol
Volume : 28
Pages : 253

Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance.

Authors : Van Damme M, Crompot E, Meuleman N, Maerevoet M, Mineur P, Bron D, Lagneaux L, Stamatopoulos B
Year : 2016
Journal : Clin Epigenetics
Volume : 8
Pages : 132

Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.

Authors : Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F, Wynendaele W, Gil T, Schatteman P, Filleul B, Schallier D, Machiels JP, Schrijvers D, Everaert E, Dhont L, Werbrouck P, Vermeij J, Mebis J, Clausse M, Rasschaert M, Van Erps J, Verheezen J, Van Haverbeke J, Goeminne JC, Lumen N
Year : 2016
Journal : Urol Oncol
Volume : 34(6)
Pages : 254.e7-254.e13

Approach and complications associated with suburethral synthetic slings in women: Systematic review and meta-analysis.

Authors : Biardeau X, Zanaty M, Aoun F, Benbouzid S, Peyronnet B
Year : 2016
Journal : Prog Urol
Volume : 26(4)
Pages : 254-69

Continuous Renal Replacement Therapy for Acute Renal Failure in Patients with Cancer: A Well-Tolerated Adjunct Treatment.

Authors : Fischler R, Meert AP, Sculier JP, Berghmans T
Year : 2016
Journal : Front Med (Lausanne)
Volume : 3
Pages : 33

Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.

Authors : Woff E, Hendlisz A, Garcia C, Deleporte A, Delaunoit T, Maréchal R, Holbrechts S, Van den Eynde M, Demolin G, Vierasu I, Lhommel R, Gauthier N, Guiot T, Ameye L, Flamen P
Year : 2016
Journal : Eur J Nucl Med Mol Imaging
Volume : 43(10)
Pages : 1792-801

Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue

Authors : Kotecki N, Awada A, Bonneterre J, Hebbar M, Adenis A, Cortot AB, Cousin C, Clisant S, Duhamel A, Penel N
Year : 2016
Journal : Pharmaceutical Medicine
Volume : 30(3)
Pages : 143-7

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.

Authors : Tolaney SM, Nechushtan H, Ron IG, Schöffski P, Awada A, Yasenchak CA, Laird AD, OKeeffe B, Shapiro GI, Winer EP
Year : 2016
Journal : Breast Cancer Res Treat
Volume : 160
Pages : 305-312

Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al.

Authors : Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart-Gebhart M
Year : 2016
Journal : Ann Oncol
Volume : 27
Pages : 203-5

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.

Authors : Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ
Year : 2016
Journal : Lancet
Volume : 387(10020)
Pages : 760-9

Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.

Authors : Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J
Year : 2016
Journal : Ann Oncol
Volume : 27
Pages : v111-v118

No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.

Authors : Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, Casasnovas O, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y
Year : 2016
Journal : J Clin Oncol
Volume : 34(22)
Pages : 2568-74

Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer.

Authors : Hamm A, Prenen H, Van Delm W, Di Matteo M, Wenes M, Delamarre E, Schmidt T, Weitz J, Sarmiento R, Dezi A, Gasparini G, Rothé F, Schmitz R, Dhoore A, Iserentant H, Hendlisz A, Mazzone M
Year : 2016
Journal : Gut
Volume : 65(6)
Pages : 990-1000

Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2.

Authors : Gebhart G, Flamen P, de Vries EG, Jhaveri K, Wimana Z
Year : 2016
Journal : J Nucl Med
Volume : 57 Suppl 1
Pages : 81S-8S

Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al.

Authors : Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EGE, Piccart-Gebhart M
Year : 2016
Journal : Ann Oncol
Volume : 27
Pages : 205-207

Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies.

Authors : Lambertini M, Santoro L, Del Mastro L, Nguyen B, Livraghi L, Ugolini D, Peccatori FA, Azim HA Jr
Year : 2016
Journal : Cancer Treat Rev
Volume : 49
Pages : 65-76

Is it possible to improve communication around radiotherapy delivery: A randomized study to assess the efficacy of team training?

Authors : Liénard A, Delevallez F, Razavi D, Gibon AS, Libert Y, Delvaux N, Marchal S, Etienne AM, Bragard I, Reynaert C, Slachmuylder JL, Durieux JF, Farvacques C, Scalliet P, Van Houtte P, Coucke P, Merckaert I
Year : 2016
Journal : Radiother Oncol
Volume : 119
Pages : 361-67